Online inquiry

IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4661MR)

This product GTTS-WQ4661MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets FGFR1 gene. The antibody can be applied in Non-alcoholic steatohepatitis (NASH) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001174063.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2260
UniProt ID P11362
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4661MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3455MR IVTScrip™ mRNA-Anti-S, AZD8895(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AZD8895
GTTS-WQ3482MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BA1126
GTTS-WQ6804MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DSTP-3086S
GTTS-WQ5792MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA cetuximab-IR700
GTTS-WQ6444MR IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CT-P23
GTTS-WQ15202MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA TA-650
GTTS-WQ1807MR IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ADCT-402
GTTS-WQ237MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 14.18 mAb
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW